title: Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group.
abstract: OBJECTIVE
  To evaluate the feasibility of pulsed dose rate (PDR) brochytherapy in squamous cell anal canal carcinoma (SCACC).
  
  
  METHODS
  In this study a series of 19 patients with SCACC were included between 1995 and 1997. All patients were treated with curative intent with external beam radiotherapy (EBRT) (44-50 Gy) and one or two cycles of concomitant fluorouracilcisplatinum. After a gap of 2-3 weeks PDR interstitial brachytherapy was performed with a rigid needles technique. The dose was between 10-25 Gy (PARIS system).
  
  
  RESULTS
  All patients are alive. No severe grade 3-4 toxicity was encountered. One local relapse one metastatis were seen in two distinct patients. There was no dysfunction of the after loading machine.
  
  
  CONCLUSIONS
  The feasibility of PDR brachytherapy appears good in SCACC. It is an attractive alternative to low dose rate brachytherapy.
authors.affiliation: Service de Radiotherapie-Oncologie, Centre Hospitalier Lyon Sud, Pierre Benite, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Gerard
authors.forename: F
authors.initials: F
authors.lastname: Mauro
authors.forename: L
authors.initials: L
authors.lastname: Thomas
authors.forename: B
authors.initials: B
authors.lastname: Castelain
authors.forename: J J
authors.initials: JJ
authors.lastname: Mazeron
authors.forename: J M
authors.initials: JM
authors.lastname: Ardiet
authors.forename: D
authors.initials: D
authors.lastname: Peiffert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011832:Radiation Injuries; D011879:Radiotherapy Dosage
chemical_list: D007496:Iridium Radioisotopes